“We have reinvented everything, from the design of the building to the way ... it will spend €1.3B to build new insulin plant in Germany More recently, Sanofi last month said it would shell ...

the vaccines global business unit of Sanofi, to meet the growing demand for five-component acellular pertussis (5-acP) antigen. Due for completion in 2021, the new building will also be equipped ...

Sanofi has announced the inauguration of its new modular vaccine and biomedicine ... “We have re-invented everything, from the design of the building to the way we collaborate with health ...

Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...

Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...

One of the cornerstones of being prepared for the next pandemic is being in the best position possible to design and deploy a ...

GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For ... The deal will be funded by existing cash and new committed bank debt facilities. Net debt is expected to be approximately ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...